Cargando…
Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics
The rapid growth of COVID-19 cases is causing an increasing death toll and also paralyzing the world economy. De novo drug discovery takes years to move from idea and/or pre-clinic to market, and it is not a short-term solution for the current SARS-CoV-2 pandemic. Drug repurposing is perhaps the onl...
Autores principales: | Oerlemans, Rick, Ruiz-Moreno, Angel Jonathan, Cong, Yingying, Dinesh Kumar, Nilima, Velasco-Velazquez, Marco A., Neochoritis, Constantinos G., Smith, Jolanda, Reggiori, Fulvio, Groves, Matthew R., Dömling, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
RSC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130630/ https://www.ncbi.nlm.nih.gov/pubmed/34041486 http://dx.doi.org/10.1039/d0md00367k |
Ejemplares similares
-
From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease †
por: Göhl, Matthias, et al.
Publicado: (2022) -
The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort
por: Kjellin, Midori, et al.
Publicado: (2018) -
Boceprevir
Publicado: (2012) -
The Discovery and Development of Boceprevir: A Novel, First-generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease
por: Howe, Anita Y. M., et al.
Publicado: (2013) -
Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment
por: Chantry, AS, et al.
Publicado: (2014)